{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hou MM"],"funding":["Medical Research Council","Wellcome Trust","EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)"],"pagination":["8385"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12462441"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Clinical immunity to malaria can lead to asymptomatic infection, but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax, and a heterologous rechallenge with P. falciparum (ClinicalTrials.gov NCT03797989). Malaria-naïve adults underwent CHMI up to three times, by administration of red blood cells infected with P. vivax PvW1 clone or P. falciparum 3D7 clone. Nineteen participants underwent primary CHMI with P. vivax, 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI. Six participants who had completed P. vivax CHMI then underwent heterologous rechallenge with P. falciparum. We find that clinical immunity to P. vivax devel"],"journal":["Nature communications"],"pubmed_title":["Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection."],"pmcid":["PMC12462441"],"funding_grant_id":["106917/Z/15/Z","209200/Z/17/Z","733073","203764/Z/16/Z","226857/Z/23/Z","226857","107668/Z/15/Z","G1100086","212336","212336/Z/18/Z"],"pubmed_authors":["Salkeld J","Biswas S","Mac Lochlainn DJ","Minassian AM","Ramos Lopez F","Spence PJ","Mitton CH","Quinkert D","Lias AM","Bach FA","Thomas M","Poulton ID","Kingham L","Pipini D","Barber NM","Barrett JR","Nielsen CM","Donnellan FR","Khozoee B","Harding AC","Cho JS","Greenwood NM","Rayner JC","Rawlinson TA","Lopez Ramon R","Cowan RE","Skinner K","Silk SE","Edwards NJ","Platt A","Nahrendorf W","Kundu P","Baker M","Bardelli M","Themistocleous Y","Nugent FL","Hodgson SH","Hou MM","Draper SJ"],"additional_accession":[]},"is_claimable":false,"name":"Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.","description":"Clinical immunity to malaria can lead to asymptomatic infection, but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax, and a heterologous rechallenge with P. falciparum (ClinicalTrials.gov NCT03797989). Malaria-naïve adults underwent CHMI up to three times, by administration of red blood cells infected with P. vivax PvW1 clone or P. falciparum 3D7 clone. Nineteen participants underwent primary CHMI with P. vivax, 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI. Six participants who had completed P. vivax CHMI then underwent heterologous rechallenge with P. falciparum. We find that clinical immunity to P. vivax devel","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T09:49:02.447Z","creation":"2026-07-02T03:12:10.087Z"},"accession":"S-EPMC12462441","cross_references":{"pubmed":["40998768"],"doi":["10.1038/s41467-025-63104-y"]}}